CELZ

+ Watchlist + Portfolio

Creative Medical Technology Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.12
52-Week Range: $0.62 – $6.25
Market Cap: $8.44M
P/E (TTM): —
EPS (TTM): -2.34
Dividend Yield: —

Advanced Metrics

Price/Book: 0.96
PEG Ratio: —
Return on Equity: -77.88%
Return on Assets: -47.32%
Gross Margin: 66.87%
Operating Margin: -208004.40%
Profit Margin: 0.00%
Current Ratio: 12.91
Debt/Equity: 0.00
Total Debt: $14.19K
Free Cash Flow: $-3.46M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-362.36K

CELZ Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$88.60K	$9.00K	$11.00K	$6.00K
Cost of Revenue	$28.49K	$3.60K	$4.40K	$2.19K
Gross Profit	$60.11K	$5.40K	$6.60K	$3.81K
Research & Development	$6.27M	$1.97M	$2.40M	$2.26M
Selling, General & Admin	$3.94M	$3.56M	$3.24M	$3.76M
Operating Expenses	$10.30M	$5.63M	$5.75M	$6.15M
Operating Income	-$10.24M	-$5.62M	-$5.74M	-$6.14M
EBITDA	-$10.15M	-$5.53M	-$5.63M	-$6.02M
Pretax Income	-$10.14M	-$5.29M	-$5.49M	-$6.00M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$10.14M	-$5.29M	-$5.49M	-$6.00M
Diluted EPS	-9.28	-3.76	-3.71	-2.52
Diluted Shares	1.09M	1.41M	1.48M	2.38M

CELZ Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.32M	$3.47M	$5.94M	$7.21M
Receivables	$0.00	—	$0.00	$52.08K
Inventory	$10.19K	$6.59K	$2.19K	$0.00
Current Assets	$18.75M	$10.27M	$6.14M	$7.40M
Total Assets	$19.19M	$10.72M	$6.67M	$7.81M
Current Liabilities	$3.32M	$371.39K	$327.64K	$284.88K
Total Liabilities	$3.32M	$371.39K	$327.64K	$284.88K
Retained Earnings	-$53.81M	-$59.10M	-$64.59M	-$70.59M
Shareholders' Equity	$15.86M	$10.34M	$6.34M	$7.51M
Working Capital	$15.43M	$9.90M	$5.81M	$7.11M

CELZ Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.80M	-$8.03M	-$5.30M	-$5.86M
Capital Expenditure	—	-$100.00K	-$200.00K	—
Free Cash Flow	-$7.80M	-$8.13M	-$5.50M	-$5.86M
Depreciation & Amortisation	$92.08K	$94.58K	$110.45K	$123.33K
Stock-Based Compensation	$68.75K	$36.65K	$36.65K	$3.48K
Investing Cash Flow	-$10.08M	$3.45M	$6.32M	-$50.50K
Financing Cash Flow	$15.47M	-$270.95K	$1.45M	$7.17M
Share Repurchases	$0.00	-$270.95K	-$174.96K	-$10.00K
Net Change in Cash	-$2.40M	-$4.85M	$2.47M	$1.27M

CELZ Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$3.00K	$0.00	$0.00	$3.00K	$0.00
Cost of Revenue	$1.20K	$0.00	$0.00	$994.00	$0.00
Gross Profit	$1.80K	$0.00	$0.00	$2.01K	$0.00
Research & Development	$743.30K	$501.26K	$465.15K	$550.08K	$541.66K
Selling, General & Admin	$888.40K	$731.52K	$776.82K	$1.37M	$888.64K
Operating Expenses	$1.66M	$1.26M	$1.27M	$1.95M	$1.46M
Operating Income	-$1.66M	-$1.26M	-$1.27M	-$1.95M	-$1.46M
EBITDA	-$1.63M	-$1.23M	-$1.24M	-$1.91M	-$1.43M
Pretax Income	-$1.64M	-$1.23M	-$1.24M	-$1.89M	-$1.40M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$1.64M	-$1.23M	-$1.24M	-$1.89M	-$1.41M
Diluted EPS	-0.83	-0.48	-0.48	—	-0.38
Diluted Shares	1.98M	2.58M	2.58M	—	3.70M

CELZ Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$7.70M	$6.54M	$5.38M	$7.21M	$5.72M
Receivables	—	—	—	$52.08K	$105.71K
Inventory	$994.00	$994.00	$994.00	$0.00	—
Current Assets	$7.84M	$6.63M	$5.41M	$7.40M	$6.06M
Total Assets	$8.35M	$7.11M	$5.85M	$7.81M	$6.44M
Current Liabilities	$286.39K	$277.64K	$261.35K	$284.88K	$307.65K
Total Liabilities	$286.39K	$277.64K	$261.35K	$284.88K	$307.65K
Retained Earnings	-$66.23M	-$67.46M	-$68.70M	-$70.59M	-$71.99M
Shareholders' Equity	$8.06M	$6.83M	$5.59M	$7.51M	$6.11M
Working Capital	$7.56M	$6.36M	$5.15M	$7.11M	$5.75M

CELZ Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.59M	-$1.16M	-$1.17M	-$1.94M	-$1.32M
Capital Expenditure	—	—	—	—	-$125.00K
Free Cash Flow	-$1.59M	-$1.16M	-$1.17M	-$1.94M	-$1.45M
Depreciation & Amortisation	$30.58K	$30.74K	$31.06K	$30.95K	$28.86K
Stock-Based Compensation	$3.48K	$0.00	$0.00	$0.00	$0.00
Investing Cash Flow	$0.00	$0.00	$0.00	-$50.50K	-$175.00K
Financing Cash Flow	$3.35M	$0.00	$0.00	$3.82M	$13.36K
Share Repurchases	-$10.00K	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	$1.76M	-$1.16M	-$1.17M	$1.83M	-$1.48M

Market Snapshot

About

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on stem cell and immunotherapy technologies, headquartered in Phoenix, Arizona. The company develops and commercializes autologous cellular therapies for regenerative medicine applications, including treatments for cardiovascular disease, sexual health disorders, and wound healing. Creative Medical's technology platforms include ImmCelz, an immunotherapy for cancer treatment, and CaverStem, a cell therapy for erectile dysfunction. The company operates through its subsidiaries to develop, manufacture, and distribute stem cell-based products. Creative Medical aims to provide patients with minimally invasive treatment options using their own cells to promote tissue regeneration and healing. The company markets its therapies through a network of trained physicians and clinical partners.